In genetic diseases, the most prevalent mechanism of pathogenicity is an altered expression of dosage-sensitive genes. Drugs that restore physiological levels of these genes should be effective in treating the associated conditions. We developed a screening strategy, based on a bicistronic dual-reporter vector, for identifying compounds that modulate proteins levels, and used it in a pharmacological screening approach. To provide a proof-of-principle, we chose Autosomal Dominant LeukoDystrophy (ADLD), an ultra-rare adult-onset neurodegenerative disorder caused by lamin B1 (LMNB1) overexpression. We used a stable CHO cell line simultaneously expresses an AcGFP reporter fused to LMNB1 and a Ds-Red normalizer. Using high-content imaging analysis, we screened a library of 717 biologically active compounds and approved drugs, and identified alvespimycin, an HSP90 inhibitor, as a positive hit. We confirmed that alvespimycin can reduce LMNB1 levels by 30-80% in five different cell lines (fibroblasts, NIH3T3, CHO, COS-7 and rat primary glial cells). In ADLD fibroblasts, alvespimycin reduced cytoplasmic LMNB1 by about 50%. We propose this approach for effectively identifying potential drugs for treating genetic diseases associated with deletions/duplications, and paving the way towards phase II clinical trials. This article is protected by copyright. All rights reserved.

A high-content drug screening strategy to identify protein level modulators for genetic diseases: a proof-of-principle in Autosomal Dominant LeukoDystrophy (ADLD)

Giorgio, Elisa;Pozzi, Elisa;Ferrero, Marta;Della Sala, Edoardo;Lorenzati, Martina;Cortelli, Pietro;Buffo, Annalisa;Brusco, Alfredo
2021

Abstract

In genetic diseases, the most prevalent mechanism of pathogenicity is an altered expression of dosage-sensitive genes. Drugs that restore physiological levels of these genes should be effective in treating the associated conditions. We developed a screening strategy, based on a bicistronic dual-reporter vector, for identifying compounds that modulate proteins levels, and used it in a pharmacological screening approach. To provide a proof-of-principle, we chose Autosomal Dominant LeukoDystrophy (ADLD), an ultra-rare adult-onset neurodegenerative disorder caused by lamin B1 (LMNB1) overexpression. We used a stable CHO cell line simultaneously expresses an AcGFP reporter fused to LMNB1 and a Ds-Red normalizer. Using high-content imaging analysis, we screened a library of 717 biologically active compounds and approved drugs, and identified alvespimycin, an HSP90 inhibitor, as a positive hit. We confirmed that alvespimycin can reduce LMNB1 levels by 30-80% in five different cell lines (fibroblasts, NIH3T3, CHO, COS-7 and rat primary glial cells). In ADLD fibroblasts, alvespimycin reduced cytoplasmic LMNB1 by about 50%. We propose this approach for effectively identifying potential drugs for treating genetic diseases associated with deletions/duplications, and paving the way towards phase II clinical trials. This article is protected by copyright. All rights reserved.
HUMAN MUTATION
42
1
102
116
https://onlinelibrary.wiley.com/doi/epdf/10.1002/humu.24147
ADLD; LMNB1; alvespimycin; dosage-sensitive gene; lamin B1; pharmacological screening; rare disease; therapy
Giorgio, Elisa; Pesce, Emanuela; Pozzi, Elisa; Sondo, Elvira; Ferrero, Marta; Morerio, Cristina; Borrelli, Giusy; Della Sala, Edoardo; Lorenzati, Martina; Cortelli, Pietro; Buffo, Annalisa; Pedemonte, Nicoletta; Brusco, Alfredo
File in questo prodotto:
File Dimensione Formato  
166.ADLD alvespimycin_Hum Mut2020.pdf

non disponibili

Tipo di file: PDF EDITORIALE
Dimensione 4.61 MB
Formato Adobe PDF
4.61 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Drug repositioning_ver5.4_preprint.docx

non disponibili

Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 1.67 MB
Formato Microsoft Word XML
1.67 MB Microsoft Word XML   Visualizza/Apri   Richiedi una copia
Drug repositioning_ver5.4_preprint.pdf

accesso aperto

Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 1.33 MB
Formato Adobe PDF
1.33 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1765560
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact